'In transition' Shire strikes deal for follow-on Hunter syndrome product
This article was originally published in Scrip
Executive Summary
Shire is teaming up with biotechnology firm ArmaGen Technologies in order to develop an investigational enzyme replacement therapy (ERT) for the treatment of Hunter syndrome.